Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Gross Profit
Revenue minus cost of revenue: what remains to cover operating expenses after paying for what was sold.
Denali Therapeutics Inc.NASDAQ: DNLI
Gross Profit · Q2 FY2026 · quarter ended Jun 2026
Gross profit remains negative
Q2 FY2026 gross profit was $3.51M, compared with $0 a year earlier. Trailing-twelve-month gross profit was -$2.2M.
Context
- Gross profit increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly gross profit holds near $3.51M or moves back toward the trailing-twelve-month quarterly average of -$550K.
Sources:Income StatementText generated from reported figures; not investment advice.
Gross Profit history
USD · from the income statement
- Latest · FY2025
- (11.18M) USD
- Year-over-year change
- —
| Period | Period end | Gross Profit | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (11.18M) | — |
| FY2024 | 2024-12-31 | 0 | -100.0% |
| FY2023 | 2023-12-31 | 330.53M | +204.7% |
| FY2022 | 2022-12-31 | 108.46M | +122.9% |
| FY2021 | 2021-12-31 | 48.66M | — |
Gross Profit vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's LTM Jun 2026 gross profit of -$2.2M is the 8th highest of the 11 companies compared; the peer median is -$118.5K.
- Gross profit amounts to 61.0% of revenue for DNLI, versus a peer median of 96.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.62B | +37.2% | +24.2% | 97.8% | |
| LTM Sep 2026 | $942.72M | -1.3% | +17.4% | 98.2% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | $19M | +2140.8% | — | 95.0% |
| LTM Jun 2026 | $0 | — | — | — | |
| LTM Sep 2026 | -$108K | +99.7% | — | — | |
| LTM Mar 2026 | -$129K | — | — | — | |
| LTM Jun 2026 | -$2.07M | — | — | — | |
| LTM Jun 2026 | -$2.2M | — | — | 61.0% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | -$5.01M | — | — | — |
| LTM Mar 2026 | -$11.28M | -289.4% | -56.0% | 61.2% | |
| LTM Sep 2026 | -$77.55M | +67.5% | — | — | |
| Peer median (excluding DNLI) | -$118.5K | +52.3% | +17.4% | 96.4% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.66M | 108.46M | 330.53M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.18M |
| Gross Profit | 48.66M | 108.46M | 330.53M | 0 | (11.18M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
| Selling, General & Admin | 79.06M | 90.48M | 103.35M | 105.44M | 97.1M |
| Operating Expenses | 344.41M | 449.21M | 527.23M | 487.34M | 544.16M |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| EBITDA | (282.56M) | (315.59M) | (128.47M) | (492.89M) | (497.63M) |
| EBITDA Margin | -580.7% | -291.0% | -38.9% | — | — |
| Operating Income | (295.75M) | (340.74M) | (196.7M) | (487.34M) | (555.34M) |
| Operating Margin | -607.8% | -314.2% | -59.5% | — | — |
| Interest Income | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Income Before Tax | (291.16M) | (325.97M) | (145.19M) | (422.71M) | (512.44M) |
| Pre-Tax Margin | -598.3% | -300.5% | -43.9% | — | — |
| Income Tax Expense | (575K) | 21K | 30K | 68K | 102K |
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Net Margin | -597.2% | -300.6% | -43.9% | — | — |
| EPS (Basic) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| EPS (Diluted) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| Weighted Avg Shares | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
| Weighted Avg Shares (Diluted) | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.